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Abstract
Background: Autism spectrum disorders (ASDs) are neurodevelopmental conditions characterized by social and
behavioural impairments. In addition to neurological symptoms, ASD subjects frequently suffer from gastrointestinal
abnormalities, thus implying a role of the gut microbiota in ASD gastrointestinal pathophysiology.
Results: Here, we characterized the bacterial and fungal gut microbiota in a cohort of autistic individuals demonstrating
the presence of an altered microbial community structure. A fraction of 90% of the autistic subjects were classified as
severe ASDs. We found a significant increase in the Firmicutes/Bacteroidetes ratio in autistic subjects due to a reduction of
the Bacteroidetes relative abundance. At the genus level, we observed a decrease in the relative abundance of Alistipes,
Bilophila, Dialister, Parabacteroides, and Veillonella in the ASD cohort, while Collinsella, Corynebacterium, Dorea, and
Lactobacillus were significantly increased. Constipation has been then associated with different bacterial patterns in
autistic and neurotypical subjects, with constipated autistic individuals characterized by high levels of bacterial taxa
belonging to Escherichia/Shigella and Clostridium cluster XVIII. We also observed that the relative abundance of the fungal
genus Candida was more than double in the autistic than neurotypical subjects, yet due to a larger dispersion of values,
this difference was only partially significant.
Conclusions: The finding that, besides the bacterial gut microbiota, also the gut mycobiota contributes to the alteration
of the intestinal microbial community structure in ASDs opens the possibility for new potential intervention strategies
aimed at the relief of gastrointestinal symptoms in ASDs.
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Background
The term “autism spectrum disorders” (ASDs) refers to
a group of neurodevelopmental disorders with an early
life stage onset characterized by alterations in social
interactions and communication and by restricted and
repetitive behaviour [1]. It is now well accepted the
contribution of both genetic and environmental factors in
the aetiology of ASDs [2, 3]. Among the non-neurological
symptoms associated with ASDs, several studies indicate
gastrointestinal (GI) symptoms as common comorbidities
[4–7]. Alterations in the composition of the gut micro-
biota have been implicated in a wide variety of human dis-
eases, including ASDs [8]. Since the gut microbiota makes
critical contributions to metabolism and maintenance of
immune homeostasis and may control the central nervous
system (CNS) activities through neural, endocrine, and
immune pathways [9], it has been hypothesized the active
role of the gut microbiota in ASD pathophysiology. There
is more than a subtle link between the gut microbiota and
the CNS, through the so-called “microbiome-gut-brain
axis”. Indeed, it has been demonstrated a direct inter-
action between the gut microbiota and enteric neurons
[10, 11], its role in the regulation of the HPA axis [12],
and the production of many chemicals important in
brain functioning (e.g., serotonin, dopamine, kynure-
nine, γ-aminobutyric acid, SCFAs, p-cresol) [13, 14]. A
dysbiotic microbial community could lead to systemic
inflammation due to hyper-activation of T-helper 1 and
T-helper 17 cell responses [15] affecting also the re-
activity of peripheral immune cells to the CNS [16] and
the integrity of blood-brain barrier [17] which is known
to be altered in ASDs [18]. Several evidences suggested
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an early immune activation with chronic inflammation
and cytokine dysregulation in ASDs [19, 20], and it has
been shown that systemic inflammation induced by
LPS provokes behavioural changes and impairs the
blood-brain barrier in animal models [17, 21]. Further-
more, fungal infections that may originate from alter-
ations in commensal bacteria population [22] could
shift the indoleamine 2,3-dioxygenase’s activity [23, 24]
reducing the levels of kynurenine [25], a neuroprotec-
tive agent. Despite several reports disclosed an aberrant
gut microbiota in ASDs, consensus across studies has
not yet been established [8]. Here, we characterized the
bacterial gut microbiota and the less studied gut myco-
biota of subjects affected by autism through amplicon-
based metataxonomic analysis of the V3–V5 regions of
the prokaryotic 16S ribosomal DNA and of the internal
transcribed spacer 1 (ITS1) region of the fungal rDNA in
order to better understand the microbial community struc-
ture associated with ASDs and its involvement on GI
abnormalities.
Results
Autistic subjects harbour an altered bacterial gut microbiota
For the characterization of the gut microbiota associated
with autism, we recruited 40 autistic subjects (36 out of
40 autistic subjects were classified as severe ASDs,
Childhood Autism Rating Scale (CARS) value >37) and 40
neurotypical controls (Table 1, Additional file 1: Table S1).
Analysis of alpha diversity revealed no significant differ-
ences between autistic and neurotypical subjects (herein-
after termed AD and NT, respectively). However, the
analysis of the beta diversity calculated on the unweighted
and weighted UniFrac distances and the Bray-Curtis
dissimilarity revealed that the bacterial microbiota of AD
clusters apart from that of NT (p < 0.05, permutational
multivariate analysis of variance (PERMANOVA); Fig. 1,
Additional file 2: Table S2). Since we enrolled subjects
suffering from constipation among NT and AD subjects,
the impact of constipation on the beta diversity of the two
groups of study was also analysed. We observed that
constipation has a significant effect on the microbial
community structure within NT subjects (p < 0.05,
PERMANOVA), as expected [26, 27], but not within AD
subjects (Additional file 2: Table S2). Furthermore, we
observed that the severity of the autistic phenotype, as
measured by CARS scores, does not affect the bacterial
community structure among AD individuals (p > 0.05,
PERMANOVA; Additional file 3: Table S3).
Phylum level analysis showed a clear alteration of the
bacterial gut community in AD characterized by a higher
Firmicutes/Bacteroidetes ratio (p < 0.005, Wilcoxon rank-
sum test; Fig. 2a) in AD than that in NT due to a signifi-
cant reduction of the relative abundance of Bacteroidetes
(9.2% AD, 19.4% NT) (FDR-corrected p < 0.05, Welch t
test; Fig. 2b). Genus level analysis showed that the top ten
most abundant genera in both AD and NT subjects were
Bifidobacterium, Bacteroides, Faecalibacterium, Unknown
Lachnospiraceae, Blautia, Ruminococcus, Clostridium XI,
Streptococcus, Gemmiger, and Lachnospiraceae incertae
sedis (Additional file 4: Figure S1, Additional file 5:
Table S4). Interestingly, the genus Prevotella was only
barely represented in AD with respect to NT (0.05%
AD, 1.5% NT), in agreement with a previous study on
the gut microbiota in ASD children [28] although this
difference of relative abundance was not supported by the
statistical analysis. We further analysed the bacterial com-
munity structure associated with AD and NT by using
linear discriminant effect size (LEfSe), an algorithm for
high-dimensional biomarker discovery which uses linear
discriminant analysis (LDA) to estimate the effect size of
each taxon which is differentially represented in cases and
controls [29]. LEfSe analysis revealed a significant increase
of the relative abundance of different bacterial taxa in AD
than in NT among which Collinsella, Corynebacterium,
Dorea, and Lactobacillus and a significant reduction of
the taxa Alistipes, Bilophila, Dialister, Parabacteroides,
Table 1 Characteristics of study participants
Autistic Neurotypical
Subjects (n) 40 40
Age (1st–3rd quartile) 10 (5–17) 7 (3.6–12)
Gender (n)
Female 22.5% (9) 30% (12)
Male 77.5% (31) 70% (28)
Constipation (n)
Constipated 12.5% (5) 27.5% (11)
Non-constipated 72.5% (29) 72.5% (29)
NA 15% (6) 0% (0)
Calprotectin
(1st–3rd quartile)
36.9 (17.6–76.0) μg/g 40.9 (17–74.7) μg/g
Constipated 39.1 (22.9–70.0) μg/g 27.9 (20.3–97.6) μg/g
Non-constipated 35.9 (15.0–57.8) μg/g 50.5 (15.0–73.8) μg/g
CARS (1st–3rd quartile) 47 (40–50.5) NA
Constipated 50 (36–52.0) NA
Non-constipated 48 (42–50.0) NA
ESR (1st–3rd quartile) 7.5 (3.25–17.7) mm/h NA
Constipated 22.0 (12.0–25.0) mm/h NA
Non-constipated 7.0 (2.7–11.2) mm/h NA
Serum IgA
(1st–3rd quartile)
131.0 (70.0–172.2) mg/ml NA
Constipated 97.0 (82.0–153.0) mg/ml NA
Non-constipated 133.0 (67.0–181.0) mg/ml NA
Data expressed as medians with interquartile ranges when applicable.
AD autistic subjects, NT neurotypical subjects, NA not applicable,
CARS Childhood Autism Rating Scale, ESR erythrocyte sedimentation rate
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and Veillonella in AD than in NT (p < 0.01, Wilcoxon
rank-sum test; LDA >2.0; Fig. 3).
Constipation selects different bacterial taxa in autistic
subjects and neurotypical healthy controls
Autistic subjects frequently suffer of GI comorbidities
[4–7], and constipation is a GI symptom often reported in
these subjects, known to alter the physiology of the hu-
man GI tract and the gut microbiota itself [27, 30, 31].
Correlation analysis of the bacterial relative abundances
between constipated and non-constipated subjects, both
autistic and neurotypical, revealed that among the most
abundant bacterial genera (with relative abundance >0.5%
and detectable in at least the 70% of the investigated
subjects), the taxa Gemmiger and Ruminococcus anticorre-
lates with the constipation status (Spearman’s correlation
r = −0.39 and −0.36, respectively; FDR-corrected p < 0.05;
Additional file 6: Table S5) while Escherichia/Shigella and
Clostridium cluster XVIII positively correlates with this GI
symptom (Spearman’s correlation r = 0.31 and 0.38,
respectively; FDR-corrected p < 0.05; Additional file 6:
Table S5). We further compared the relative abundance of
these taxa among constipated and non-constipated sub-
jects within and between groups. We observed that
Escherichia/Shigella and Clostridium cluster XVIII were
significantly more abundant in constipated AD compared
to the non-constipated ones (FDR-corrected p < 0.05,
Wilcoxon rank-sum test; Fig. 4a, b) while no differences
have been detected between constipated and non-
constipated NT for these taxa. On the other hand, the
genus Gemmiger was significantly less abundant in consti-
pated compared to non-constipated NT (FDR-corrected
p < 0.05, Wilcoxon rank-sum test; Fig. 4c). Remarkably, no
significant differences have been observed in the levels of
faecal calprotectin between AD and NTas well as between
constipated and non-constipated subjects in both groups
(Table 1 and Additional file 1: Table S1). Furthermore, we
analysed the levels of other two biomarkers of inflam-
mations, i.e., serum IgA and ESR in the autistic sub-
jects, and we did not observe significant differences
among constipated and non-constipated AD (Table 1
and Additional file 1: Table S1). Therefore, while con-
stipation resulted in a significant increase of Escherichia/
Shigella and Clostridium cluster XVIII, no differences have
A B C
Fig. 1 PCoA of bacterial beta diversity based on the a unweighted and b weighted UniFrac distances and c Bray-Curtis dissimilarity. Autistic and
neurotypical subjects are coloured in orange and blue, respectively. The constipation status of the subjects is indicated according to different shapes,
circles for non-constipated and triangles for constipated individuals
A B
Fig. 2 a Mean relative abundances (%) of Firmicutes and Bacteroidetes in autistic (AD) and neurotypical (NT) subjects; *p < 0.005, Wilcoxon rank-sum test
on the Firmicutes/Bacteroidetes ratio. b Welch’s t test statistics of the relative abundances of bacterial phyla in autistic and neurotypical subjects. Orange
bars indicate significant FDR-corrected p values adjusted for multiple comparison controlling the family-wise type I error rate
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been observed in the levels of inflammation between con-
stipated and non-constipated autistic subjects suggesting
that constipation and the related alterations of the gut
microbiota in autistic subjects as well as in neurotypical
individuals are not associated with an increase of intestinal
inflammation. It should be noted that the number of
enrolled constipated subjects was quite low and therefore
these analyses could be underpowered.
Autistic subjects harbour an altered gut mycobiota
We then investigated the gut mycobiota of our study
cohort through amplicon-based sequencing of fungal
ITS1 region. High-quality fungal sequences were
detected respectively in 35 out of 40 autistic subjects
and 38 out of 40 NT. As occurred for the bacterial gut
microbiota, we did not observe significant differences in
fungal alpha diversity between AD and NT. The analysis
of beta diversity revealed that the gut mycobiota of AD
was different compared to NT as calculated by principal
coordinates analysis (PCoA) and PERMANOVA on the
weighted UniFrac distance and Bray-Curtis dissimilarity
(p < 0.05; Fig. 5). As for the bacterial beta diversity, con-
stipation showed a significant effect within NT subjects
(p = 0.046, PERMANOVA on Bray-Curtis dissimilarities)
but not within AD subjects (Additional file 7: Table S6).
Furthermore, the severity of the autistic phenotype
does not affect the gut mycobiota community struc-
ture among AD individuals (p > 0.05, PERMANOVA;
Additional file 3: Table S3). An in-depth analysis of
the gut mycobiota leads to the identification of 50
fungal taxa fully classified to the genus level and 30
only partially classified. Genus level analysis showed
A
B
Fig. 3 a Cladograms generated by LEfSe indicating differences in the bacterial taxa between autistic (AD) and neurotypical (NT) subjects. Nodes
in orange indicate taxa that were enriched in AD compared to those in NT, while nodes in blue indicate taxa that were enriched in NT compared
to those in AD. b LDA scores for the bacterial taxa differentially abundant between autistic (AD) and neurotypical (NT) subjects. Positive and
negative LDA scores indicate the bacterial taxa enriched in NT and AD subjects, respectively. Only the taxa having a p < 0.01 (Wilcoxon rank-sum
test) and LDA >2.0 are shown in the figure legend
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Aspergillus (24.2% AD; 28% NT), Candida (37.7% AD;
14.1% NT), Penicillium (13.2% AD; 23.5% NT) and
Malassezia (3.05% AD; 3.3% NT) as the most abundant
and widely distributed genera in our study cohort in terms
of relative abundance (Additional file 8: Figure S2,
Additional file 9: Table S7). The relative abundance of the
genus Candida was more than twice as much in AD than
NT, yet due to a large dispersion of values (p < 0.001;
Levene’s test), this difference was only partially significant
(Welch t test, FDR-corrected p value = 0.09, uncorrected
p value = 0.006; Additional file 10: Figure S3). The super-
imposition of the most abundant genera over the PCoA
A B C
Fig. 4 Box plot representation of the relative abundances of bacterial genera correlating with the constipation status of the subjects enrolled in
this study. Comparisons between a and b constipated (C) and non-constipated (NC) autistic subjects and (c) constipated (C) and non-constipated
(NC) neurotypical subjects; Asterisk indicates FDR-corrected p < 0.05, Wilcoxon rank-sum test
A
B
Fig. 5 PCoAs of fungal beta diversity based on a weighted UniFrac distance and b Bray-Curtis dissimilarity. The right panel of the graphs a and b
shows the same PCoA coordinates with the most abundant OTUs superimposed as coloured squares, with the size being proportional to the mean
relative abundance of the taxon across all samples (grey dots). Autistic and neurotypical subjects are colored in orange and blue, respectively. The
constipation status of the subjects is indicated according to different shapes, circles for non-constipated and triangles for constipated individuals
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plots revealed that high levels of Candida abundance was
associated with a group of subjects mainly affected by aut-
ism (Fig. 5) suggesting that Candida indeed could
play a role in the altered microbial community associ-
ated with the autistic subjects. Correlation analyses
among the most abundant fungi and bacteria (with
relative abundance >0.5% and detectable in at least the
70% of the investigated subjects) revealed no significant
correlations among autistic subjects while a significant
positive correlation between the genera Aspergillus and
Bifidobacterium was found within neurotypical individuals
(Spearman’s r = 0.6, FDR-corrected p = 0.004) (Additional
file 11: Table S8).
Discussion
The gut microbiota is a crucial factor for the mainten-
ance of the GI tract functions and immune homeostasis.
It is well known that dysbiosis of the GI tract could lead
to inflammation and immune activation in several path-
ologies [15]. The frequent occurrence of GI symptoms
in autistic subjects imply the possible involvement of the
gut microbiota in ASD gastrointestinal pathophysiology,
further supported by the speculations on the increased
incidence of ASD cases due to “Western” habits (i.e.,
diet, medications, and excessive overall hygiene) that can
affect the composition of the gut microbiota [32].
Several studies demonstrated alterations in the bacterial
gut microbiota of ASD individuals, even if the differ-
ences reported in these studies were in some cases
discordant, possibly due to variance in sampling strat-
egies and methodologies used [8]. In addition, our recent
findings showed an altered gut microbiota in Rett syn-
drome [33], a genetically determined neurodevelopmen-
tal disorder previously categorized in the ASD group
sharing some features of these conditions. We character-
ized the gut microbiota associated with autism, disclos-
ing an altered microbial community both at bacterial
and fungal level. We observed a significant increase in
the Firmicutes/Bacteroidetes ratio in autistic subjects
due to a significant reduction of Bacteroidetes in these
individuals. Several inflammatory conditions have been
related to an increase in the Firmicutes/Bacteroidetes
ratio such as inflammatory bowel diseases (IBDs) [34]
and obesity [35]. Consistently with these observations,
an increased Firmicutes/Bacteroidetes ratio has been
reported also in subjects with autism [36, 37]. Further-
more, we discovered that the relative abundances of the
genera Collinsella, Corynebacterium, Dorea, and Lactoba-
cillus were significantly increased in the gut microbiota of
autistic subjects with respect to that of the neurotypical
subjects while the relative abundance of the genera
Alistipes, Bilophila, Dialister, Parabacteroides, and Veillo-
nella were significantly reduced in these individuals. A re-
cent study on a mouse model of ASDs demonstrated that
treatments with a PSA+ Bacteroides fragilis strain restore
autism-related behavioural and GI abnormalities, also
reducing the reported high levels of Lachnospiraceae and
4-ethylphenyl sulfate, a metabolite produced by this
bacterial family related to p-cresol, a putative metabolic
marker for autism [38]. Overall, these data are consistent
with our findings and remark the importance of Bacteroi-
detes in ASD pathophysiology. Moreover, Lactobacillus
resulted to be enriched in the gut microbiota of autistic
individuals while Dialister and Veillonella resulted to be
depleted, in line with the results obtained in previous
studies [28, 39]. Since constipation is a common gastro-
intestinal problem in subjects with ASDs [4–7], we com-
pared our data between constipated and non-constipated
subjects in order to evaluate the contribution of constipa-
tion in shaping the gut microbiota of autistic subjects.
Indeed, it has been proposed that GI symptoms may be
related to ASDs [40]. The evidence that the taxa belonging
to the Clostridium cluster XVIII and the putative pro-
inflammatory Escherichia/Shigella [41, 42] positively
correlated with the constipation status of the subjects as
well as their enrichment in constipated autistic subjects
supports the hypothesis that GI problems and related
alterations of the gut microbiota may contribute to ASD
gastrointestinal symptoms [40]. Because of their ability to
produce exotoxins and propionate that may exacerbate
autistic symptoms [43], the role of clostridia in ASDs has
been extensively explored. The species belonging to the
Clostridium cluster XVIII have been shown to produce
exotoxins [44] and to promote conditions favouring in-
flammation [45, 46] although other studies observed their
potential ability to induce homeostatic T-reg responses
[47]. It is also interesting to underline the occurrence of a
subclinical acute phase response in ASD plasma, as
evidenced by advanced proteomic analysis [48].
Despite the importance given to the implications of
the gut microbiota in health and disease, few reports
have explored the relevance of the fungal component of
the gut microbiota in GI (patho) physiology [49]. Further-
more, none of the published studies on ASDs’ gut micro-
biota have assessed the fungal gut community structure
associated with autism. Our dataset of autistic subjects
displayed a different fungal community structure com-
pared to neurotypical subjects. In particular, the genus
Candida was one of the most abundant taxa in the gut
mycobiota of this study cohort, being two times more
abundant in AD than in NT. To the best of our know-
ledge, this is the first time that alterations of the intestinal
fungal microbiota are associated with ASDs. Although
Candida is one of the most common and abundant genus
of the human gut mycobiota [50, 51], its implication in
phenomena of fungal dysbiosis have been reported in
several GI and inflammatory conditions [52–54] as well as
in Rett syndrome [33]. It is therefore possible that
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alteration of the intestinal fungal population driven by an
expansion of Candida in the gut mycobiota of autistic in-
dividuals may negatively impact on GI abnormalities
through cytokine dysregulation. The gut microbiota, in
particular some species of Lactobacillus, modulates the
immunological responses to Candida in the GI tract by
providing tryptophan-derived aryl hydrocarbon receptor
ligands that stimulate the immune system, principally
ILC3 cells, to produce IL-22 [55]. Together with IL-17, IL-
22 avoids the excessive proliferation of Candida and other
fungal commensals in the gut. It is therefore possible that
alterations of the gut microbiota in ASDs could lead to an
expansion of the Candida population preventing from full
restoration of the bacterial community structure. Indeed,
it has been observed that alterations of the bacterial
gut microbiota due to prolonged antibiotic usage and
the subsequent colonization with C. albicans interfere
with the reassembly of the bacterial community struc-
ture, resulting in altered abundances of Bacteriodetes,
Lactobacillaceae, Ruminococcaceae, and Lachnospira-
ceae [56]. Since the two different microbial communi-
ties (fungi and bacteria) mutually influence, we could
also speculate that the reduced early life encounters
with foodborne and environmental bacteria and fungi
in urban areas of the globalized world could be a
cause of the increased colonization with some major
commensals, such as the pathobionts Candida and
Escherichia. The alteration of the composition of the
gut microbiota could also be mediated by mechanism
of trained immunity [57] or by a reduced ability of
the immune system to control its overgrowth due to
lack of immune training, extending the hygiene hy-
pothesis [58] from bacteria to yeasts [59].
Conclusions
Here, we observed an altered intestinal microbial
community associated with ASDs, both at bacterial
and fungal level not depending by the constipation
status of autistic individuals but rather by the autistic
disorder itself. However, due to the broad phenotyp-
ical variability of ASDs, an in-depth characterization
of the genetic and phenotypical background in a
larger cohort of ASD individuals would be necessary
to comprehensively understand the role of the gut
microbiota in ASDs pathophysiology and to further
validate these findings. Our results therefore encour-
age new extensive, multicentric studies on the impact
of the bacterial and fungal components of the gut
microbiota in the gastrointestinal physiology and
neuroplastic changes in ASDs, as well as the integra-
tion of such data with genetics, immunology, and
metabolomics to further establish the relevance of the
gut microbiota in the ASDs.
Methods
Study participants and samples’ handling and collection
We recruited 40 subjects with clinical diagnosis of
autism (average age 11.1 ± 6.8; sex, male:female, 31:9)
and we compared them with 40 age and sex-matched
neurotypical healthy subjects (average age 9.2 ± 7.9; sex,
male:female, 28:12). Autistic subjects with clinically
evident inflammatory conditions were excluded. Consti-
pation and inflammation (i.e., serum IgA, erythrocyte
sedimentation rate, and faecal calprotectin levels) were
also assessed. The autistic subjects were consecutively
admitted to the Child Neuropsychiatry Unit of the
University Hospital of Siena, and ASDs were diagnosed
according with the Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition [1], and evaluated using
Autism Diagnostic Observation Schedule and Autism
Behaviour Checklist. Childhood Autism Rating Scale
(CARS) scores [60] were calculated by an experienced
child neuropsychiatrist. Average CARS values were
46.2 ± 6.8 (value range 32–57); a fraction of 90% (36/40)
were classified as severe ASDs (CARS value >37), with
10% (4/40) being moderately severe ASDs (CARS values
from 30 to 36) (Additional file 12: Table S9). No specific
comorbidities in the autistic cohort were present with the
single exception of a coexisting celiac disease in two
patients (5%).
Constipation has been defined according to Rome III
criteria [61]. Stool samples from enrolled subjects were
collected, aliquoted as it is, and stored at −80 °C until
analysis. All subjects of this study were under a
Mediterranean-based diet, and no antibiotics, probiotics,
or prebiotics have been taken in the 3 months prior to
the sample collection. None of the subjects were on
anti-inflammatory or antioxidant drugs. The study was
conducted after the approval by the Institutional Review
Board of the Siena University Hospital (AOUS, Siena,
Italy) and all written informed consents were obtained
from either the parents or the legal tutors of the enrolled
subjects, in compliance with national legislation and the
Code of Ethical Principles for Medical Research Involving
Human Subjects of the World Medical Association
(Declaration of Helsinki).
Faecal calprotectin assay
Calprotectin determination was performed by using a
polyclonal antibody in an enzyme-linked immunosorbent
assay (Calprest, Eurospital, Trieste, Italy) according to the
manufacturer’s instructions. Calprotectin values <50 μg/g
per stool sample were considered normal.
Pyrosequencing and data analysis
Total DNA extraction from faecal samples (250 mg, wet
weight) was performed using the FastDNA™ SPIN Kit
for Feces (MP Biomedicals, Santa Ana, CA, USA)
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following manufacturer’s instructions. For each DNA
sample, we amplified respectively the bacterial 16S rRNA
genes using a primer set specific for V3–V5 hypervari-
able regions (F357: 5′-TCCTACGGGAGGCAGCAG-3′
and R937: 5′-TGTGCGGGCCCCCGTCAATT-3′) and the
internal transcribed spacer (ITS) using a primer set specific
for fungal ITS1 rDNA region (18SF: 5′-GTAAAAGTCG-
TAACAAGGTTTC-3′ and 5.8S1R: 5′-GTTCAAAGAYT
CGATGATTCAC-3′) [62] containing adaptors, key
sequence, and barcode sequences as described by the 454
Sequencing System Guidelines for Amplicon Experimental
Design (Roche, Basel, Switzerland). The PCR products
obtained were then purified, quantified, and pooled in
equimolar way in a final amplicon library. The 454 pyrose-
quencing was carried out on the GS FLX+ system using
the XL+ chemistry following the manufacturer’s recom-
mendations (Roche, Basel, Switzerland). Raw 454 data were
demultiplexed using the Roche’s sff file software and
submitted to the European Nucleotide Archive (ENA) with
accession numbers PRJEB15418 and PRJEB15420. Sample
accessions IDs and metadata are available in Additional
file 12: Table S9. Reads were preprocessed using the
MICCA pipeline (v. 0.1) (http://www.micca.org/) [63].
Operational taxonomic units (OTUs) were assigned by
clustering the sequences with a threshold of 97% pairwise
identity andv their representative sequences were classi-
fied using the RDP classifier version 2.7 on 16S data and
using the RDP classifier version 2.8 [64] against the
UNITE fungal ITS database [65] on ITS1 data. Template-
guided multiple sequence alignment (MSA) was per-
formed using PyNAST [66] (v. 0.1) against the multiple
alignment of the Greengenes [67] database (release 13_05)
filtered at 97% similarity for bacterial sequences and
through de novo MSA using T-Coffee [68] for fungal
sequences. Fungal taxonomy assignments were then
manually curated using BLASTn against the GenBank’s
database for accuracy. High-quality fungal sequences have
been also manually filtered out for sequences belonging to
Agaricomycetes (unlikely to be residents of the human gut
due to their ecology [69]). The phylogenetic tree was
inferred using micca-phylogeny [70]. Sampling heterogen-
eity was reduced by rarefaction. Alpha (within-sample
richness) and beta-diversity (between-sample dissimilarity)
estimates were computed using the phyloseq R package
[71]. PERMANOVA test was performed using the adonis()
function in the R package vegan with 999 permutations.
Permutations have been constrained within age groups
(corresponding to 0–2, 3–10, 11–17, and >18 years old) or
gender to evaluate possible biases related to the unequal
age and gender distributions among subjects using the
“strata” argument within the adonis() function. Two-sided,
unpaired Welch t statistics were computed using the
function mt() in the phyloseq library and the p values were
adjusted for multiple comparisons controlling the family-
wise type I error rate (minP procedure) [72]. Spearman’s
correlation tests were computed using the psych R pack-
age [73]. Linear discriminant effect size (LEfSe) analysis
was performed to find features (taxa) differentially repre-
sented between autistic and neurotypical subjects. LEfSe
combines Kruskal-Wallis test or pairwise Wilcoxon rank-
sum test with linear discriminant analysis (LDA). It ranks
features by effect size, which put features that explain
most of the biological difference at top. LEfSe analysis
was performed under the following conditions: α
value for the statistical test equal to 0.01 and thresh-
old on the logarithmic LDA score for discriminative
features equal to 2.0 [29]. All statistical analyses were
performed using R [74], and p values were FDR cor-
rected [75].
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